Dow Jones
38.571,03 -115,27 (-0,30%) Nasdaq
16.828,67 +93,67 (+0,56%) Nikkei 225
38.837,46 -85,54 (-0,22%) EUR/USD
1,0903 -0,0004 (-0,03%) Bitcoin EUR
63.198,72 +4,87 (+0,01%) CMC Crypto 200
1.441,71 -5,44 (-0,38%)
Clearside Biomedical, Inc. (CLSD)
Dopo ore:
- GlobeNewswire
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial wer
- GlobeNewswire
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical tri
- GlobeNewswire
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm Shifting Therapeutic Innovations in Ophthalmology will take place on October
